NCT00319046View on ClinicalTrials.gov

Clinical Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Miglustat in Patients With Stable Type 1 Gaucher Disease

PHASE3CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

February 1, 2006

Primary Completion Date

June 1, 2010

Study Completion Date

July 1, 2010

Conditions
Gaucher Disease Type 1
Interventions
DRUG

Miglustat

Oral capsules containing miglustat 100 mg, administered three times daily (t.i.d.)

Sponsors

Lead Sponsor

Actelion
All Listed Sponsors
lead

Actelion

INDUSTRY